SCHEMBL12352467

SCHEMBL12352467

Cc1cn([C@@H]2CC(OC(=O)c3ccccc3)[C@H](COC(=O)c3ccccc3)O2)c(=O)n(C)c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASE1 P07998 1/20 0.58
POLB P06746 2/20 0.47
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
UPP1 Q16831 1/20 0.42
NPC1 O15118 1/20 0.41
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
KMT2A Q03164 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA5 P30532 1/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA4 P43681 1/20 0.40
GAPDH P04406 2/20 0.39
PPM1B O75688 1/20 0.38
KCNH2 Q12809 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2623806 1.00 RNASE1 (0.58) RNASE1POLBALDH1A1HTTUPP1
SCHEMBL12352466 0.90 RNASE1 (0.50) RNASE1POLBALDH1A1HTTUPP1
SCHEMBL2623808 0.90 RNASE1 (0.50) RNASE1POLBALDH1A1HTTUPP1
SCHEMBL14263441 0.87 RNASE1 (0.56) RNASE1POLBALDH1A1HTTUPP1
SCHEMBL22992340 0.83 RNASE1 (0.82) RNASE1
SCHEMBL13273339 0.83 RNASE1 (0.82) RNASE1
SCHEMBL30976654 0.83 RNASE1 (0.82) RNASE1
SCHEMBL9326675 0.83 RNASE1 (0.82) RNASE1
SCHEMBL21886791 0.83 RNASE1 (0.82) RNASE1
SCHEMBL9324478 0.83 RNASE1 (0.82) RNASE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195922-A9 Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B IDENIX PHARMACEUTICALS, INC. (US) 2011-08-11 US disclosed
US-7858594-B2 Crystalline and amorphous forms of beta-L-2′-deoxythymidine NOVARTIS PHARMA AG (CH) 2010-12-28 US disclosed
US-20100152126-A1 Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B IDENIX PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
US-20100048504-A1 CRYSTALLINE AND AMORPHOUS FORMS OF BETA-L-DEOXYTHYMIDINE NOVARTIS AG (CH) 2010-02-25 US disclosed
US-7323451-B2 Crystalline and amorphous forms of beta-L-2′-deoxythymidine IDENIX PHARMACEUTICALS, INC. (US) 2008-01-29 US disclosed
US-7304043-B2 β-L-2′-deoxy-nucleosides for the treatment of hepatitis B IDENIX PHARMACEUTICALS, INC. (US) 2007-12-04 US disclosed
US-20070087995-A1 beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B IDENIX PHARMACEUTICALS, INC. (US) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070087995-A1 beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B PNP, DUT, ATIC RNASE1 473/4885POLB 65/4885ALDH1A1 2036/4885
US-20100152126-A1 Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B PNP, DUT, ATIC RNASE1 473/4885POLB 65/4885ALDH1A1 2036/4885
US-20100048504-A1 CRYSTALLINE AND AMORPHOUS FORMS OF BETA-L-DEOXYTHYMIDINE TYMP, PYGL, TTR RNASE1 50/4885POLB 263/4885ALDH1A1 1075/4885
US-20110195922-A9 Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B PNP, DUT, ATIC RNASE1 473/4885POLB 65/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.